120 related articles for article (PubMed ID: 6708051)
1. In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: 1H and 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution.
Borch RF; Hoye TR; Swanson TA
J Med Chem; 1984 Apr; 27(4):490-4. PubMed ID: 6708051
[TBL] [Abstract][Full Text] [Related]
2. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways.
Zon G; Ludeman SM; Brandt JA; Boyd VL; Ozkan G; Egan W; Shao KL
J Med Chem; 1984 Apr; 27(4):466-85. PubMed ID: 6708049
[TBL] [Abstract][Full Text] [Related]
3. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of activation of 4-hydroxycyclophosphamide.
Borch RF; Millard JA
J Med Chem; 1987 Feb; 30(2):427-31. PubMed ID: 3806624
[TBL] [Abstract][Full Text] [Related]
5. O-Methylhydroxylamine as a new trapping reagent for quantitative studies of 4-hydroxycyclophosphamide and aldophosphamide.
Zon G; Ludeman SM; Sweet EM; Egan W; Phillips LR
J Pharm Sci; 1982 Apr; 71(4):443-6. PubMed ID: 7086655
[TBL] [Abstract][Full Text] [Related]
6. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
7. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
8. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin.
Kwon CH; Maddison K; LoCastro L; Borch RF
Cancer Res; 1987 Mar; 47(6):1505-8. PubMed ID: 3815352
[TBL] [Abstract][Full Text] [Related]
9. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. 2. Direct observation, characterization, and reactivity studies of iminocyclophosphamide and related species.
Boyd VL; Summers MF; Ludeman SM; Egan W; Zon G; Regan JB
J Med Chem; 1987 Feb; 30(2):366-74. PubMed ID: 3806617
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of "phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aldophosphamide.
Ludeman SM; Boyd VL; Regan JB; Gallo KA; Zon G; Ishii K
J Med Chem; 1986 May; 29(5):716-27. PubMed ID: 3701785
[TBL] [Abstract][Full Text] [Related]
11. Determination of 4-hydroxycyclophosphamide in plasma, as 2,4-dinitrophenylhydrazone derivative of aldophosphamide, by liquid chromatography.
Johansson M; Bielenstein M
J Chromatogr B Biomed Appl; 1994 Oct; 660(1):111-20. PubMed ID: 7858703
[TBL] [Abstract][Full Text] [Related]
12. Base-catalyzed hydrolysis of 4-hydroperoxycyclophosphamide: evidence for iminocyclophosphamide as an intermediate.
Borch RF; Getman KM
J Med Chem; 1984 Apr; 27(4):485-90. PubMed ID: 6708050
[TBL] [Abstract][Full Text] [Related]
13. Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases.
Manthey CL; Sladek NE
Biochem Pharmacol; 1988 Jul; 37(14):2781-90. PubMed ID: 3395357
[TBL] [Abstract][Full Text] [Related]
14. The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy.
Dirven HA; Venekamp JC; van Ommen B; van Bladeren PJ
Chem Biol Interact; 1994 Dec; 93(3):185-96. PubMed ID: 7923439
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, activation, and cytotoxicity of aldophosphamide analogues.
Borch RF; Valente RR
J Med Chem; 1991 Oct; 34(10):3052-8. PubMed ID: 1920356
[TBL] [Abstract][Full Text] [Related]
16. Aldophosphamide: synthesis, characterization, and comparison with "Hohorst's aldophosphamide".
Struck RF
Cancer Treat Rep; 1976 Apr; 60(4):317-9. PubMed ID: 1277207
[TBL] [Abstract][Full Text] [Related]
17. Effect of stereochemistry on the oxidative metabolism of the cyclophosphamide metabolite aldophosphamide.
Habib AD; Boal JH; Hilton J; Nguyen T; Chang YH; Ludeman SM
Biochem Pharmacol; 1995 Jul; 50(3):429-33. PubMed ID: 7646546
[TBL] [Abstract][Full Text] [Related]
18. Effects of N-substitution on the activation mechanisms of 4-hydroxycyclophosphamide analogues.
Kwon CH; Borch RF
J Med Chem; 1989 Jul; 32(7):1491-6. PubMed ID: 2738883
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis.
Belfayol-Pisanté L; Guillevin L; Tod M; Fauvelle F
Fundam Clin Pharmacol; 2000; 14(4):415-21. PubMed ID: 11030450
[TBL] [Abstract][Full Text] [Related]
20. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers.
Low JE; Borch RF; Sladek NE
Cancer Res; 1983 Dec; 43(12 Pt 1):5815-20. PubMed ID: 6640533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
